Mark Pykett

MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders.

MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders.

MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders.

Part of Cordlife Group Ltd., Cytomatrix is a company that researches, develops, and commercializes novel cell growth systems for hematopoietic (blood) stem cells. The company is based in Woburn, MA. The company was founded by Mark Jerome Pykett. Cytomatrix was acquired by Cordlife Group Ltd. on April 30, 2003 for $11 million.

Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France.

Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover.

Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover.

Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France.

Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France.

Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover.

Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover.